

Press release

Lund, SWEDEN – April 16, 2010

Hansa Medical's rights issue oversubscribed

The preliminary outcome of Hansa Medical's rights issue shows that the rights issue has been oversubscribed by 22 % and that 94 % of the shares has been subscribed through preferential rights.

The rights issue will raise SEK 27 million to Hansa Medical before issue expenses. The final result of the rights issue will be published around April 20, 2010.

Persons who have subscribed to shares without preferential rights will be assigned shares according to the principles accounted for in the Swedish rights issue prospectus. Notice of shares assignment will be communicated around April 20, 2010. Only persons assigned shares will be notified.

Rights issue in brief

Hansa Medical's Board of Directors decided March 4, 2010 to implement a new issue of 3,863,184 shares at a price of SEK 7 each. At full subscription, the share issue raises SEK 27 million before issue expenses. Shareholders in Hansa Medical AB had preferential rights to the subscription of new shares and one existing share entitled to subscription of one new share. The share issue was fully secured by Farstorp Invest AB. The subscription period was from March 24 through April 14, 2010.

The reason underlying the new share issue is to secure favourable development of the company's principal projects anti-alpha-11, IdeS and HMD-301. The funds from the rights issue will primarily be allocated to identification of an anti-alpha-11 lead candidate and production of IdeS.

For more information, please contact:

Hansa Medical AB

Emanuel Björne, CEO

Mobile: +46 707 175477

E-mail: emanuel.bjorne@hansamedical.com

Bo Håkansson, Chairman of the board

Mobile: +46 705 98 57 22

E-mail: boh@farstorp.com

ABOUT HANSA MEDICAL

Hansa Medical is a preclinical and early clinical biopharmaceutical development company focused on inflammation. The company develops three product candidates; IdeS, anti-alpha-11 and HMD-301. IdeS is a novel treatment prior to organ transplantation. Anti-alpha-11 is a novel and more specific rheumatoid arthritis treatment. HMD-301 is a novel diagnostic method for diagnosis and prognosis of severe sepsis. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.

Hansa Medical AB
P.O. Box 785
SE-220 07 Lund, SWEDEN
TELEFON +46 46 16 56 70
TELEFAX +46 46 12 77 75
info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Scheelevägen 22
Lund, SWEDEN